NCT07362810
G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 6 words
- Trial sites expanded: 3 → 7 locations
- Start date changed from estimate of Jan 1, 2026 to Jan 22, 2026
- Collaborators expanded, about 41 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
hematopoietic engraftment time (including granulocyte engraftment and platelet engraftment)
Timeframe: Data on engraftment will be collected daily from stem cell infusion (Day 0) until the occurrence of both engraftment events or up to a maximum of 100 days, whichever comes first.
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Timeframe: Adverse events are monitored from the time of enrollment (first study intervention) through the end of the study, with an expected average follow-up of 12 months.
Secondary (1)
progression-free survival (PFS) and overall survival (OS)
Arms and interventions
G-CSF+IL-11Experimental
rhG-CSF 5 μg/kg/day for 6 days plus rhIL-11 50 μg/kg/day for 5 days
G-CSFActive comparator
rhG-CSF 5 μg/kg/day subcutaneously for 6 days.
Drugs: G-CSF+IL-11, G-CSF Granulocyte-Colony Stimulating Factor
Sites
7 sites in 1 country